Omeros (NASDAQ:OMER) reported higher third-quarter sales of its transplant complication treatment YARTEMLEA and a second consecutive quarter of positive operating cash flow, while a non-cash adjustment tied to its convertible notes pushed the company to a net loss.
YARTEMLEA generated $35.9 million...